Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UCSPE
ADC Name
wO2024239281A1 c263 7.6
Synonyms
C263
   Click to Show/Hide
Organization
HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD | ZHAO, ROBERT YONGXIN | HANGZHOU DAC BIOTECH CO., LTD
Drug Status
Investigative
Drug-to-Antibody Ratio
7.6
Structure
Antibody Name
vandortuzumab
  Antibody Info 
Antigen Name
Metalloreductase STEAP1 (STEAP1)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.81
nM
Undisclosed
Prostate carcinoma
Half Maximal inhibitory Concentration (lC50) 
0.85
nM
CVCL_4784
Prostate carcinoma
Half Maximal inhibitory Concentration (lC50) 
68.3
nM
CVCL_1045
Prostate carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.81 nM
Method Description
MTT assays of the Steap1-ADCs against tumor cells of PC3-4H7, at 6000 cells, 96 h incubation
In Vitro Model Prostate carcinoma PC3-4H7 cells Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.85 nM
Method Description
MTT assays of the Steap1-ADCs against tumor cells of C4-2B, at 6000 cells, 96 h incubation
In Vitro Model Prostate carcinoma C4-2B cells CVCL_4784
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
68.3 nM
Method Description
MTT assays of the Steap1-ADCs against tumor cells of 22RV1, at 6000 cells, 96 h incubation
In Vitro Model Prostate carcinoma 22RV1 cells CVCL_1045
References
Ref 1 Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate